Industrial Synthesis Route for Methyl 2-(1-(Mercaptomethyl)cyclopropyl)Acetate
- Efficient multi-step synthesis starting from dibromoneopentyl glycol enables high-yield production of methyl 2-(1-(mercaptomethyl)cyclopropyl)acetate without cyanide reagents. Key process parameters—including solvent selection, temperature control, and workup protocols—are optimized for industrial purity (>98%) and scalability.
- NINGBO INNO PHARMCHEM CO.,LTD. offers this Montelukast intermediate in bulk with full COA documentation and consistent batch-to-batch quality.
Methyl 2-(1-(Mercaptomethyl)cyclopropyl)acetate—also systematically named methyl 1-(mercaptomethyl)cyclopropaneacetate (CAS 152922-73-1)—is a critical chiral building block in the synthesis of Montelukast sodium (Singulair®), a widely prescribed leukotriene receptor antagonist for asthma and allergic rhinitis. As demand for cost-effective, non-cyanide-based routes grows, manufacturers require robust, scalable processes that deliver high industrial purity while avoiding hazardous reagents like sodium cyanide or diazomethane.
Step-by-Step Industrial Synthesis Pathway
The most viable commercial route begins with readily available dibromoneopentyl glycol and proceeds through a six-step sequence designed for operational safety, yield optimization, and minimal purification burden. This method bypasses unstable intermediates such as 1-(hydroxymethyl)cyclopropyl acetonitrile, which historically plagued earlier synthetic attempts.
Stage 1: Cyclopropyl Dimethanol Formation
Dibromoneopentyl glycol undergoes zinc-mediated cyclization in ethanol or methanol under reflux (80–100 °C) to afford cyclopropyl dimethanol in 75–85% molar yield. Post-reaction treatment with ammonia precipitates zinc complexes, enabling clean isolation via vacuum distillation. GC purity consistently exceeds 98%.
Stage 2: Cyclic Sulfite Construction
Cyclopropyl dimethanol reacts with thionyl chloride in the presence of triethylamine in dichloromethane or toluene at 0–30 °C to form cyclopropyl dimethanol cyclic sulfite. Yields range from 82–88%, with the product isolated as a stable white solid suitable for direct use in the next step.
Stage 3: Thioacetic Acid-Mediated Ring Opening
The cyclic sulfite undergoes nucleophilic ring opening with potassium thioacetate in polar aprotic solvents (DMSO, DMF) at 0–100 °C, yielding 1-methylol cyclopropyl thiomethyl acetic ester—a direct precursor to the target molecule. Optimized conditions (e.g., DMSO at 50 °C) deliver up to 84% isolated yield of this key intermediate.
Stage 4: Activation and Hydrolysis to Final Product
While full conversion to the free acid (1-thiopurine methyltransferase cyclopropyl acetic acid) involves mesylation/tosylation followed by cyanide displacement and alkaline hydrolysis, the methyl ester variant—methyl 2-(1-(mercaptomethyl)cyclopropyl)acetate—can be accessed more directly via controlled esterification or by halting the sequence at the thioester stage and performing mild transesterification. This avoids prussiate entirely and aligns with green chemistry principles.
When sourcing high-purity Methyl 1-(Mercaptomethyl)cyclopropaneacetate, buyers should verify that the supplier employs cyanide-free protocols and provides comprehensive Certificate of Analysis (COA) data including HPLC, GC, NMR, and residual solvent profiles.
Process Advantages Over Legacy Routes
Traditional syntheses relied on diethyl malonate alkylations or itaconic anhydride cyclizations, often requiring toxic cyanide salts or explosive diazomethane. In contrast, the modern route leverages:
- Cheap, commodity feedstocks (dibromoneopentyl glycol, zinc, thioacetic acid)
- No cyanide or diazomethane usage, enhancing workplace safety and regulatory compliance
- High cumulative yield (>50% over 4–5 steps vs. <30% in older methods)
- Simplified workup: no chromatography needed; products isolated by extraction and distillation
Technical Specifications and Bulk Supply
NINGBO INNO PHARMCHEM CO.,LTD., a premier global manufacturer of advanced pharmaceutical intermediates, produces methyl 1-(mercaptomethyl)cyclopropaneacetate at multi-hundred-kilogram scale with stringent quality controls. The compound is supplied as a colorless to pale yellow liquid with typical specifications:
| Parameter | Specification |
|---|---|
| CAS Number | 152922-73-1 |
| Chemical Name | Methyl 2-[1-(mercaptomethyl)cyclopropyl]acetate |
| Molecular Formula | C₇H₁₂O₂S |
| Industrial Purity (GC/HPLC) | ≥98.0% |
| Appearance | Colorless to pale yellow liquid |
| Bulk Packaging | 25 kg drums or 200 kg IBC totes |
| Documentation | Full COA, MSDS, GMP audit support |
As a trusted partner in API supply chains, NINGBO INNO PHARMCHEM CO.,LTD. ensures consistent manufacturing process validation, enabling reliable delivery of this essential Montelukast intermediate with competitive bulk pricing and short lead times.
Conclusion
The industrial synthesis of methyl 2-(1-(mercaptomethyl)cyclopropyl)acetate has evolved significantly toward safer, higher-yielding, and more economical protocols. By eliminating cyanide-dependent steps and optimizing reaction conditions for scalability, modern routes meet the stringent demands of global pharmaceutical production. For manufacturers seeking a dependable source of this high-value intermediate, NINGBO INNO PHARMCHEM CO.,LTD. stands out as a leader in both technical execution and commercial reliability.